image credit: Freepik

T-knife bags $110M for raft of cell therapy solid tumor trials

Investors have flocked to T-knife Therapeutics, which has been taking aim at solid tumors, an area where cell therapies have struggled to perform as well as they have in some blood cancers. Just last year, the biotech raised €66 million ($78 million) and now has reeled in a further $110 million to support a multifront push into clinical trials.

Berlin-based T-knife was founded to build on years of work to develop a transgenic mouse capable of facilitating the discovery of humanized T-cell receptors (TCRs). The work has given T-knife a platform that leverages natural selection to generate high-affinity human TCRs.

Read More on FierceBiotech